{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:31:12Z","timestamp":1787725872629,"version":"build-2784847793"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jgo.2026.102905","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:38:53Z","timestamp":1771065533000},"page":"102905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world management and clinical outcomes of first line treatment of advanced renal cell carcinoma in older patients in Canada"],"prefix":"10.1016","volume":"17","author":[{"given":"Lauren","family":"Curry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Arenovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Tanguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aly-Khan A.","family":"Lalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Yick Chin","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimal","family":"Bhindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen S.","family":"Basappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg A.","family":"Bjarnason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney H.","family":"Breau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Castonguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Soulieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Pouliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Bosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian K.","family":"Kollmannsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Finelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Fallah-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Soleimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2026.102905_bb0005","series-title":"Japanese journal of clinical oncology","first-page":"657","article-title":"Overview of clinical management for older patients with renal cell carcinoma","volume":"Vol. 52","author":"Numakura","year":"2022"},{"issue":"3","key":"10.1016\/j.jgo.2026.102905_bb0010","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jgo.2021.11.011","article-title":"International trends in cancer incidence in middle-aged and older adults in 44 countries","volume":"13","author":"Pilleron","year":"2022","journal-title":"J Geriatr Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2026.102905_bb0015","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jgo.2021.02.022","article-title":"Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) \u2013 an International mRCC Database Consortium (IMDC) analysis","volume":"12","author":"Araujo","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2026.102905_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.jgo.2026.102905_bb0025","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jgo.2026.102905_bb0030","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jgo.2026.102905_bb0035","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.jgo.2026.102905_bb0040","series-title":"Current oncology reports","first-page":"562","article-title":"Immune checkpoint inhibitors in geriatric oncology","volume":"vol. 26","author":"Cook","year":"2024"},{"key":"10.1016\/j.jgo.2026.102905_bb0045","series-title":"Cancer Immunology, Immunotherapy","first-page":"1355","article-title":"First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis","volume":"vol. 72","author":"Fujiwara","year":"2023"},{"issue":"13","key":"10.1016\/j.jgo.2026.102905_bb0050","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1200\/JCO.2015.63.5839","article-title":"Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small cell lung cancer: the Phase III randomized ESOGIA-GFPC-GECP 08-02 Study","volume":"34","author":"Corre","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2026.102905_bb0055","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clgc.2021.12.003","article-title":"Utilization and safety of ipilimumab plus nivolumab in a real-world cohort of metastatic renal cell carcinoma patients","volume":"20","author":"Thana","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.jgo.2026.102905_bb0060","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.jgo.2026.102905_bb0065","first-page":"78","article-title":"Older adult participation in cancer clinical trials: a systematic review of barriers and interventions","volume":"71","author":"Sedrak","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jgo.2026.102905_bb0070","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaging.2012.12.006","article-title":"Relationship goals of middle-aged, young-old, and old-old internet daters: an analysis of online personal ads","volume":"27","author":"Alterovitz","year":"2013","journal-title":"J Aging Stud"},{"issue":"3","key":"10.1016\/j.jgo.2026.102905_bb0075","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_100038","article-title":"Why and how to integrate early palliative care into cutting-edge personalized cancer care","volume":"44","author":"Petrillo","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"14","key":"10.1016\/j.jgo.2026.102905_bb0080","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jgo.2026.102905_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100450","article-title":"Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN renal 101","volume":"7","author":"Tomita","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.jgo.2026.102905_bb0090","first-page":"64","article-title":"Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"5","author":"Bosma","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.jgo.2026.102905_bb0095","series-title":"European urology focus","first-page":"403","article-title":"Immunotherapy in the elderly","volume":"Vol. 3","author":"Lalani","year":"2017"},{"issue":"7","key":"10.1016\/j.jgo.2026.102905_bb0100","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jgo.2020.06.012","article-title":"Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers","volume":"11","author":"Schulz","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"14","key":"10.1016\/j.jgo.2026.102905_bb0105","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1002\/cncr.34230","article-title":"Frailty and checkpoint inhibitor toxicity in older patients with melanoma","volume":"128","author":"Bruijnen","year":"2022","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.jgo.2026.102905_bb0110","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jgo.2026.102905_bb0115","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/annonc\/mds431","article-title":"Safety and activity of sunitinib in elderly patients (\u226570 years) with metastatic renal cell carcinoma: a multicenter study","volume":"24","author":"Brunello","year":"2013","journal-title":"Ann Oncol"},{"issue":"11\u201312Suppl7","key":"10.1016\/j.jgo.2026.102905_bb0120","doi-asserted-by":"crossref","first-page":"S252","DOI":"10.5489\/cuaj.4293","article-title":"Can individualized sunitinib dose and schedule changes optimize outcomes for kidney cancer patients?","volume":"10","author":"Bjarnason","year":"2016","journal-title":"Can Urol Assoc J"},{"issue":"30_suppl","key":"10.1016\/j.jgo.2026.102905_bb0125","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/jco.2014.32.30_suppl.265","article-title":"Reporting on quality indicators in renal cell carcinoma: proportion of metastatic patients who initially commence on full-dose targeted therapy","volume":"32","author":"Wood","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jgo.2026.102905_bb0130","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40266-016-0390-1","article-title":"Efficacy of sunitinib in elderly patients with metastatic renal cell carcinoma: data from real-world clinical practice","volume":"33","author":"Poprach","year":"2016","journal-title":"Drugs Aging"},{"issue":"5","key":"10.1016\/j.jgo.2026.102905_bb0135","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jgo.2020.12.008","article-title":"Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: older patients more prone to toxicity","volume":"12","author":"Hermansen","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2026.102905_bb0140","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/cncr.29773","volume":"122","author":"Kaymakcalan","year":"2016","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jgo.2026.102905_bb0145","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.clgc.2014.02.009","article-title":"Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population","volume":"12","author":"Khambati","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.jgo.2026.102905_bb0150","series-title":"Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients","author":"Beltran-Bless","year":"2024"},{"issue":"6","key":"10.1016\/j.jgo.2026.102905_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2024.101811","article-title":"Selecting the right treatment: health outcome priorities in older patients with bladder cancer","volume":"15","author":"Rutten","year":"2024","journal-title":"J Geriatr Oncol."}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826000597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826000597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:49:47Z","timestamp":1774885787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406826000597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1879406826000597"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2026.102905","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world management and clinical outcomes of first line treatment of advanced renal cell carcinoma in older patients in Canada","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2026.102905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102905"}}